Freedom to Heal Act of 2025
- Sponsor
- Sen. Booker, Cory A. [D-NJ]
- Committees
- Judiciary Committee (primary)
- Last action
- Dec 4, 2025
Bottom line
The bill aims to streamline access for terminally ill patients to experimental Schedule I drugs under the Right to Try law by creating a dedicated DEA registration process for administering these substances.
What it actually does
This bill establishes a special registration process under the Controlled Substances Act (CSA) for physicians to administer Schedule I investigational drugs to eligible patients under the existing Federal Right to Try law. It mandates the Attorney General to register physicians who meet specific criteria, including evidence of compliance with the Right to Try Act, manufacturer agreements, and state law authorization. The bill also sets timelines for application approval and requires the Attorney General to issue implementing rules.
Proponents argue
Supporters argue that this bill removes a significant bureaucratic hurdle, allowing terminally ill patients to more easily access potentially life-saving experimental treatments that are currently classified as Schedule I controlled substances. They contend it aligns the Controlled Substances Act with the intent of the Federal Right to Try law, ensuring that physicians can legally administer these drugs without fear of federal prosecution, thereby expanding options for patients with no other hope.
Opponents contend
Critics may raise concerns about the potential for diversion of Schedule I controlled substances, even in a medical context, and the administrative burden on the Drug Enforcement Administration (DEA) to manage a new registration category. They might also express apprehension regarding patient safety, arguing that while the Right to Try law exists, loosening controls on Schedule I drugs, even for investigational use, could lead to unforeseen risks without the full rigor of FDA oversight.
The bill is concise and relatively easy to read, making it accessible for a quick evaluation by an informed reader.
Section 2, Controlled Substances Act (21 U.S.C. 823) subsection (p)(2)
Establishment of Special Registration for Schedule I Investigational Drugs
This provision mandates the Attorney General to create a special registration process for physicians. This registration will specifically allow physicians to directly administer eligible investigational drugs classified under Schedule I of the Controlled Substances Act to eligible patients, as defined by the Federal Right to Try law. This is intended to bridge the gap between the Right to Try law and the strict regulations governing Schedule I substances.
Supporters argue
Proponents argue that this provision is essential to fully realize the intent of the Right to Try Act by removing the federal legal ambiguity for physicians administering Schedule I investigational drugs. They believe it will provide hope and potential treatment avenues for terminally ill patients who have exhausted all other options.
Critics contend
Opponents or those with concerns might argue that creating a special registration for Schedule I drugs, even for investigational use, could inadvertently increase the risk of diversion or misuse, given the high control status of these substances. They may also question the DEA's capacity to effectively manage this new oversight role without compromising its core mission.
Tradeoffs
This provision navigates the tension between expanding access to experimental treatments for critically ill patients and maintaining strict federal control over Schedule I controlled substances to prevent abuse and diversion.
Section 2, Controlled Substances Act (21 U.S.C. 823) subsection (p)(3)(A)
Physician Application Requirements
This section outlines the specific information physicians must submit to the Attorney General to obtain the special registration. Key requirements include proof of existing controlled substance registration, documentation from the drug manufacturer or sponsor verifying the drug's eligibility and agreement to supply, an affirmation that the physician will follow manufacturer guidance, details on drug quantity, state law compliance, relevant training, and a description of the storage and administration site. This ensures a structured and accountable application process.
Section 2, Controlled Substances Act (21 U.S.C. 823) subsection (p)(3)(B) and (p)(5)
Expedited Approval and Supplemental Notification Process
The bill mandates that the Attorney General must either register an applicant or issue an order to show cause within 45 days of receiving a complete application. Furthermore, if a physician needs additional quantities of the drug, they can submit a supplemental notification, which is deemed approved after 30 days unless the Attorney General issues a show cause order. This aims to ensure a relatively swift process for both initial registration and subsequent drug acquisition.
Section 2, Controlled Substances Act (21 U.S.C. 823) subsection (p)(7) and (p)(8)
Mandatory Rulemaking for Implementation
This provision requires the Attorney General to issue an interim final rule within 240 days of the bill's enactment to implement the new special registration process. This rule must cover practical aspects such as drug delivery, storage, security, record maintenance, and procedures for registration renewal, suspension, or revocation, as well as measures to prevent diversion. A final rule must then be issued within two years of the interim rule. This ensures that the operational details of the new system are established through formal regulation.
The bill defines 'eligible investigational drug' and 'eligible patient' by directly referencing section 561B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb-0a), which is the Federal Right to Try law.
Section 2, Controlled Substances Act (21 U.S.C. 823) subsection (p)(1)
Why it matters:This is standard legislative practice to avoid redundancy and ensure consistency with existing law. It's not necessarily evasive but requires external knowledge.
Case for: Referencing existing law ensures that the new CSA registration aligns perfectly with the established criteria for the Right to Try program, preventing conflicting definitions and streamlining regulatory coherence.
Case against: For readers unfamiliar with the Federal Right to Try Act, this cross-reference makes the bill less self-contained and requires additional research to grasp the full scope of which drugs and patients are covered.
Estimated impact: The impact is significant as it entirely dictates the universe of drugs and patients to which this special registration applies, directly linking the bill's effect to the parameters of the Right to Try law.
The bill allows a physician to use a single registration for multiple treatment sites if all sites are within the same city or county and are under the control of the same institution, organization, or agency, provided the Attorney General is notified of each site.
Section 2, Controlled Substances Act (21 U.S.C. 823) subsection (p)(6)
Why it matters:This is a practical administrative detail designed to reduce burden for multi-site healthcare providers, a common feature in regulatory statutes. It's standard practice.
Case for: This provision significantly reduces administrative burden for physicians and institutions operating multiple treatment locations within a localized area, streamlining the process and making it easier to provide consistent care to eligible patients.
Case against: No specific opposition is typically raised against such administrative streamlining provisions, as they generally improve efficiency without compromising core regulatory goals, provided proper notification is maintained.
Estimated impact: This provision will primarily impact larger healthcare systems or academic medical centers that might have multiple clinics or facilities within a single geographic area, simplifying their compliance with the new registration.